OOIR: Observatory of International Research

Papers

(The TQCC of Hematological Oncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma	62
Competitive evolved sub‐clonal BCR::ABL1 and novel MSI2::PC fusion genes in myelodysplastic syndrome with isolated del(5q)	46
Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases	45
CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study	33
SUBCLONAL HETEROGENEITY DRIVING PROGRESSION AND TRANSFORMATION IN CHRONIC LYMPHOCYTIC LEUKEMIA	30
REAL‐WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA	27
Response‐adapted mosunetuzumab for untreated follicular and marginal zone lymphomas: significant monotherapy activity seen in results of an interim efficacy analysis	25
Autologous and allogeneic stem‐cell transplantation for transformed Waldenström macroglobulinemia	25
PHASE 1 TRIAL OF KT‐413, A DEGRADER OF IRAK4 AND IMID SUBSTRATES, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMAS	25
Regulatory approvals and survival benefit for novel lymphoma drugs from 2013–2022	25
Impact of COVID‐19 infection on bispecific antibodies treatment in patients diagnosed with B‐cell lymphoproliferative disorders	23
Health‐related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso‐cel in TRANSCEND CLL 004	22
AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY	21
Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis	21
IMMUNOTHERAPY ALONE VERSUS CHEMOIMMUNOTHERAPY AS FIRST‐LINE TREATMENT OF MARGINAL ZONE LYMPHOMA (MZL): A REAL‐WORLD ANALYSIS	21
BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient‐Derived Models	20
T cell CD62L expression following nivolumab therapy is associated with response to rituximab‐nivolumab in treatment naïve follicular lymphoma: the 1st FLOR study	20
CLINICAL OUTCOMES BY PROGRESSION OF DISEASE WITHIN 24 MONTHS (POD24) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) TREATED WITH LINPERLISIB	19
NOTCH PATHWAY MUTATION CONTRIBUTES TO INFERIOR PROGNOSIS IN HBV‐INFECTED CHRONIC LYMPHOCYTIC LEUKEMIA	18
A MULTI‐CENTER RETROSPECTIVE STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NK/T‐CELL LYMPHOMA	18
Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study	18
Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)	17
A PHASE I STUDY OF SPLIT‐COURSE BRIDGING RADIOTHERAPY (SC‐BRT) PRIOR TO COMMERCIAL CD19 CAR T‐CELL THERAPIES FOR PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL LYMPHOMAS	17
CLinicopathological characteristics of extranodal marginal zone B‐cell lymphoma of the intestine: a single center analysis	17
MINIMAL RESIDUAL DISEASE STATUS IMPROVED THE RESPONSE EVALUATION IN PATIENTS WITH WALDENSTRöM’S MACROGLOBULINEMIA	17

RADIOTHERAPY BRIDGING IN LARGE B‐CELL LYMPHOMA PATIENTS RECEIVING CD19 CAR‐T – THE UK EXPERIENCE	17
RITUXIMAB‐CONTAINING COMBINED MODALITY THERAPY IN LIMITED STAGE FOLLICULAR LYMPHOMA: MATURE FOLLOW UP AND DERIVATION OF A NOVEL PROGNOSTIC SCORE FROM THE TROG99.03 TRIAL	16
‘Don’t keep me waiting’: estimating the impact on lifetime survival and QALYs of reduced vein‐to‐vein time for LBCL patients treated with CAR T in the 3L+ setting	15
Quality of life and response shift effect of diffuse large B‐cell lymphoma French patients included in prospective real‐life REALYSA cohort in the first year after diagnosis	15
PATTERNS OF CIRCULATING NK CELL DYSFUNCTION IN PATIENTS WITH LYMPHOMA	15
IMPACT OF TUMOR MUTATIONAL BURDEN ON THE RESPONSE TO IMMUNOCHEMOTHERAPY IN FOLLICULAR LYMPHOMA	14
Safety and Efficacy of Acalabrutinib, Bendamustine, and Rituximab in Patients with Treatment‐Naive or Relapsed/Refractory Mantle Cell Lymphoma: Phase Ib Trial	14
OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)	14
NEW DRUG DEVELOPMENT IN LYMPHOMA OF CHINA IS GOING GLOBAL	14
SOLUBLE MACROPHAGE MARKER SCD163 PREDICTS OUTCOME IN BOTH CHEMOIMMUNOTHERAPY AND TARGETED THERAPY TREATED MANTLE CELL LYMPHOMA	13
Genomic Correlates of Radiosensitivity in Diffuse Large B Cell Lymphoma	13
Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study	13
BISPECIFIC ANTI‐CD20/19 CAR‐T—ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL—INTERIM ANALYSIS RESULTS OF DALY‐II‐USA STUDY	12
IBRUTINIB PLUS BR OR R‐CHOP IN PREVIOUSLY TREATED PATIENTS WITH FOLLICULAR OR MARGINAL ZONE LYMPHOMA: THE PHASE 3 SELENE STUDY	12
VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.	12
Machine Learning‐Based Stem Cell‐Like Phenotype Identification and Novel Risk Stratification in Diffuse Large B‐Cell Lymphoma: Multi‐Omics Data from Multicenter Studies	12
SINGLE CELL LANDSCAPE OF MULTICENTRIC CASTLEMAN DISEASE IN IDENTICAL TWINS	12
Molecular features possessed in the ctDNA reveal heterogeneity and predict outcome in newly diagnosed peripheral T‐cell lymphoma	12
Combination of the PD‐1 inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B‐cell Lymphoma: Results from a Phase I/II Study	12
PHASE 1B OPEN‐LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (LOTIS‐7)	12
Treatment outcomes of Limited Stage Grade 3A Follicular Lymphoma	11
TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)—A COHORT FROM THE ELM‐2 STUDY	11
A Retrospective Analysis of Clinical Characteristics, Treatment, and Outcomes in Large B‐cell Lymphomas with Synchronous Systemic and Central Nervous System Involvement	11
CHARACTERISTICS AND TREATMENT OUTCOMES OF AGGRESSIVE HIGH GRADE B CELL LYMPHOMA WITH MYC AND BCL 6 REARRANGEMENTS	11
CELL‐FREE DNA KINETICS DECIPHER POTENTIAL MECHANISMS OF ACTION OF IBRUTINIB COMBINATION THERAPY IN MANTLE CELL LYMPHOMA (MCL)	11
DIVERSITY OF INTRATUMORAL REGULATORY T CELLS IN B‐CELL NON‐HODGKIN LYMPHOMA	11
EFFECTS OF ALTERNATING MAGNETIC FIELD ON THE EXPRESSION OF ACTIVATION MARKERS CD154 AND CD69 IN JURKAT CELL LINE	10
Issue Information	10
Prognostic factors of children and adolescents with T‐cell acute lymphoblastic leukemia after allogeneic transplantation	10
BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED CD30‐POSITIVE PERIPHERAL T‐CELL LYMPHOMAS: REAL‐WORLD DATA	10
HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATE	10
Heat shock protein 90 inhibitors induce cell differentiation via the ubiquitin‐dependent aurora kinase A degradation in a MPLW515L mouse model of primary myelofibrosis	10
Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma	10
Study of the efficacy of novel bispecific antibodies targeting immune checkpoints in a 3D model of B non‐Hodgkin lymphoma	10
How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B‐cell lymphoma?	10
FIRST IN HUMAN STUDY OF AUTO4, A TRBC1‐TRAGETTING CART T CELL THERAPY IN RELAPSED/REFRACTORY TRBC1‐POSITIVE PERIPHERAL T‐CELL LYMPHOMA	10
	9
Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems	9
PHASE 1 RESULTS OF ANTI‐PD‐LIGAND 1 (DURVALUMAB) & LENALIDOMIDE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA AND CORRELATION WITH GENE EXPRESSION PROFILE	9
SUBTYPES OF MALIGNANT LYMPHOMAS IN UKRAINE, ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE UKRAINIAN LYMPHOMA REGISTRY	9
PRMT5 INHIBITION RESTARTS A PRO‐APOPTOTIC PROGRAM AND CREATES VULNERABILITY TO COMBINATION TREATMENT WITH BCL‐2 INHIBITOR VENETOCLAX IN MANTLE CELL LYMPHOMA	9
PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐ A JOINT ANALYSIS OF TWO CLINICAL DATABASES	9
CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)	9
The Role of 24‐Month Progression‐Free Survival (PFS24) in the Long‐Term Evaluation of Patients With Diffuse Large B Cell Lymphoma (DLBCL): A Real‐World Single Center Study	9
Impact of C‐MYC/BCL2 Double Expression on Survival Outcomes After Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma—A Nationwide Retrospective Analysis in Singapore	9
CAR‐HEMATOTOX: A DISCRIMINATIVE MODEL FOR CAR T‐CELL RELATED HEMATOTOXICITY IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA	9
GLYCOPROTEIN PTGDS ACTS AS A POTENTIAL TARGET IN DIFFUSE LARGE B‐CELL LYMPHOMA BY REGULATING MYH9‐WNT‐β‐CATENIN/STAT3 AXIS	9
TRACKING CLONAL HEMATOPOIESIS IN PATIENTS WITH CLASSICAL HODGKIN'S LYMPHOMA	9
R‐GDP SCHEDULE IN PATIENTS WITH REFRACTORY OR RELAPSED B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)	9
BENDAMUSTINE‐RITUXIMAB COMPARED TO RITUXIMAB‐CHOP/CVP FOR TREATMENT OF PATIENTS WITH INDOLENT LYMPHOMA IN ONTARIO: A POPULATION‐BASED STUDY	9

IMMUNE AND VIRUS‐SPECIFIC RESPONSES IN PARTICIPANTS WITH PRIMARY EFFUSION LYMPHOMA RECEIVING LENALIDOMIDE, DOSE‐ADJUSTED EPOCH, AND RITUXIMAB (EPOCH‐R²)	9
Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT‐Lymphoma) of the Intestine: A Single Center Analysis	9
SARCOPENIA IS AN INDEPENDENT PROGNOSTIC FACTOR IN ELDERLY MALE PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: RESULTS FROM A MULTICENTER EXPERIENCE	9
RITUXIMAB AND NONPEGYLATED LIPOSOMIAL DOXORUBINCIN (R‐NPLD) TREATMENT IN PATIENTS 80 YEARS OF AGE OR OLDER AFFECTED BY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL): A 2020 UPDATE AND IMPLICATIONS OF CLINICAL	9
PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLECLEUCEL (TISA‐CEL) INFUSION IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)	9
EPSTEIN‐BARR VIRUS‐DRIVEN DISEASES: A MULTINATIONAL, MULTICOHORT, OPEN‐LABEL PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF TABELECLEUCEL USING AN ADAPTIVE STUDY DESIGN	8
MTV, TLG AND SUV MAX AS PROMISING PARAMETERS TO PREDICT EARLY RESPONSE IN PATIENTS WITH HL TREATED WITH ABVD. A RETROSPECTIVE SUB‐ANALYSIS OF THE GATLA‐LH‐05 TRIAL	8
THE POTENTIAL EFFICACY AND MECHANISM OF BENDAMUSTINE IN ENTRA‐NODAL NK/T CELL LYMPHOMA	8
AUTOLOGOUS TRANSPLANT IN ELDERLY PATIENTS WITH R/R AGGRESSIVE LYMPHOMA SELECTED BY SIMPLIFIED CGA: THE RECANZ PROSPECTIVE PHASE 2 STUDY BY THE FONDAZIONE ITALIANA LINFOMI	8
BASELINE METABOLIC TUMOR VOLUME AND IPS PREDICT ABVD FAILURE IN ADVANCED‐STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET SCAN AFTER 2 CHEMOTHERAPY CYCLES. A RETROSPECTIVE ANALYSIS FROM THE GITIL/FI	8
PREDICTION OF RELAPSE BY STANDARDIZED IG‐BASED ALLEL‐SPECIFIC QPCR, DDPCR AND AMPLICON NGS FOR MRD MONITORING IN MANTLE CELL LYMPHOMA: A COMPARATIVE ANALYSIS BY THE EU‐MCL NETWORK	8
THE ROLE OF MULTIPARAMETRIC FLOW CYTOMETRY IN DETECTING AND CHARACTERIZING GAMMA‐DELTA T‐CELL ENTITIES IN PERIPHERAL BLOOD. SINGLE‐CENTER CASE SERIES AND LITERATURE REVIEW	8
EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3‐YEAR FOLLOW‐UP	8
INTEGRATION OF BASELINE METABOLIC PARAMETERS AND MUTATIONAL PROFILE PREDICTS OUTCOME IN DLBCL PATIENTS. A POST HOC ANALYSIS OF SAKK38/07 STUDY	8
A UK POPULATION‐BASED STUDY OF NON‐HODGKIN LYMPHOMA IN TEENAGERS AND YOUNG ADULTS (TYA) DELAYED DIAGNOSIS AND DEATH	8
A NON‐INTERVENTIONAL STUDY OF OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (URBAN): IMPACT OF COVID‐19 PANDEMIC ON ENROLLMENT AND SAFETY	8
A PHASE II STUDY OF ACALABRUTINIB IN COMBINATION WITH R‐CHOP CHEMOTHERAPY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA	8
FAVOURABLE PROGNOSTIC ROLE OF HIGH BASAL MAXIMAL STANDARDIZED UPTAKE VALUE IN FOLLICULAR LYMPHOMA	8
PROSPECTIVE VALIDATION OF RECIL RESPONSE CRITERIA: RESULTS OF OBINUTUZUMAB‐GDP AS SALVAGE PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IN AGGRESSIVE B CELL LYMPHOMA	8
A GENE SIGNATURE TO PREDICT RISK OF TRANSFORMATION IN PATIENTS WITH FOLLICULAR LYMPHOMA	8
IRONOMYCIN KILLS DIFFUSE LARGE B‐CELL LYMPHOMA CELLS BY TARGETING CELLULAR IRON HOMEOSTASIS	8
ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY	8
TARGETING PROXIMAL BCR SIGNALING PATHWAY IN DIFFUSE LARGE B‐CELL LYMPHOMA	8
A CONTINUOUS INDIVIDUALIZED RISK INDEX FOR REFINED OUTCOME PREDICTION AFTER TARGETED THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CIRI‐CLL)	8
IMMUNE PRIMING WITH NIVOLUMAB FOLLOWED BY NIVOLUMAB & RITUXIMAB IN 1^ST LINE TREATMENT OF FOLLICULAR LYMPHOMA: THE PHASE 2 1^ST FLOR STUDY	8
OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR LARGE B‐CELL LYMPHOMA: RESULTS OF THE GLA/DRST REAL WORLD ANALYSIS	8
MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA	7
CYTIDINE DEAMINASES SHAPE THE GENOME OF GERMINAL CENTER B CELL DERIVED LYMPHOMA	7
WHOLE GENOME SEQUENCING OF MATCHED PRIMARY AND RELAPSED DLBCL REVEALS DISTINCT EVOLUTIONARY DYNAMICS ASSOCIATED WITH RELAPSE TIMING	7
R‐CODOX‐M/R‐IVAC IN HIGH RISK AND MYC MUTATED DIFFUSE LARGE B CELL LYMPHOMA‐ A SINGLE CENTRE RETROSPECTIVE STUDY	7
USE OF METHOTREXATE, WHATEVER KIDNEY FUNCTION, WITH A SIMPLE ALGORITHM, RADICALLY CHANGES THE PROGNOSIS OF POST‐TRANSPLANT CNS LYMPHOMAS	7
CLADRIBINE AS FRONTLINE TREATMENT OF HAIRY CELL LEUKEMIA: A MULTICENTER EUROPEAN EXPERIENCE OF MORE THAN 30 YEARS ON 384 PATIENTS	7
COMPARATIVE EVALUATION OF RADIATION THERAPY TECHNIQUES FOR MEDIASTINUM IRRADIATION IN LYMPHOMA PATIENTS USING IMRT, B‐VMAT, 3DCRT	7
SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)	7
PUBLICATION	7
CLINICAL OUTCOMES OF RELAPSED HODGKIN LYMPHOMA PATIENTS AFTER CONTEMPORARY FIRST‐LINE TREATMENT: RESULTS FROM THE GERMAN HODGKIN STUDY GROUP	7
OUTCOME OF PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA AFTER HIGH‐DOSE METHOTREXATE FOLLOWED BY CONSOLIDATION WHOLE‐BRAIN RADIOTHERAPY AND CYTARABINE	7
PHASE IB/II STUDY OF LENALIDOMIDE, RITUXIMAB, HIGH‐DOSE METHOTREXATE (R2‐MTX) REGIMEN, FOLLOWED BY LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA	7
T‐CELL SUBSET COMPOSITION AND FUNCTIONALITY IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA	7
BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND VENETOCLAX IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAAG TRIAL OF THE GCLLSG	7
FRACTIONATED TOTAL‐BODY IRRADIATION AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM‐CELL SUPPORT IN PATIENTS WITH T‐CELL LYMPHOBLASTIC LYMPHOMA	7
REAL WORLD OUTCOME IN MANTLE CELL LYMPHOMA: A FRENCH RETROSPECTIVE STUDY IN ELDERLY PATIENTS BETWEEN 2005 AND 2018	7
PET‐ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH‐05 TRIAL	7
CLINICAL UTILITY OF INTERIM CT SCANS IN PATIENTS RECEIVING CHEMOIMMUNOTHERAPY FOR FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA	7
A novel clinical immune‐related prognostic model predicts the overall survival of mantle cell lymphoma	6
EFFECTIVENESS OF THERAPY WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	6
PROGNOSTIC ROLE OF LESION DISSEMINATION FEATURE (DMAX) CALCULATED ON BASELINE PET/CT IN HODGKIN LYMPHOMA	6
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997–20	6
Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis	6
Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia	6
First external validation of the FLIPI‐L score in a single‐center series of patients with follicular lymphoma	6
The course of patients with hairy cell leukemia during the omicron surge of the Covid‐19 pandemic	6
Unmet clinical needs in the use of zanubrutinib in malignant lymphomas (Waldenström macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma): A consensus‐based position paper from an ad hoc	6
Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma	6
EARLY SAFETY AND EFFICACY DATA FROM A PHASE I/II TRIAL OF DZD4205, A SELECTIVE JAK1 INHIBITOR, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA	6
	6
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis	6
	6
Pirarubicin‐based intensive chemotherapy followed by consolidative high‐dose chemotherapies for peripheral T‐cell lymphomas: A noncomparative phase 2 study	6
Long‐term follow‐up and health‐related quality of life among cancer survivors with stage IEA orbital‐type lymphoma after external photon‐beam radiotherapy: Results from a longitudinal study	6
Prognostic impact of complex karyotype on post‐transplant outcomes of myelofibrosis	6
A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016	6
Racial differences in the survival of mantle cell lymphoma patients in the United States	6
Report of PRPF19 as a novel partner of RARG and the recurrence of interposition‐type fusion in variant acute promyelocytic leukemia	6
High inter‐follicular spatial co‐localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma	6
Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk‐adapted, response‐adapted, and safer than before	6
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement	6
Issue Information	6
Sinonasal B‐cell lymphomas: A nationwide cohort study, with an emphasis on the prognosis and the recurrence pattern of primary diffuse large B‐cell lymphoma	6
A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma—Outcomes indicative for improved survival overtime	6
Efficacy and safety of PD‐1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study	6
Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma	5
TRACES OF EPSTEIN BARR VIRUS (EBV) ARE NOT INVOLVED IN THE PATHOGENESIS OF DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)	5
Ibrutinib combined with low‐dose histone deacetylases inhibitor chidamide synergistically enhances the anti‐tumor effect in B‐cell lymphoma	5
A 9‐LNCRNA SIGNATURE FOR PREDICTING PROGNOSIS AND IMMUNE RESPONSE IN DIFFUSE LARGE B‐CELL LYMPHOMA	5
INTEGRATING MULTI‐OMICS ANALYSIS AND ASPARAGINASE ACTIVITY CURVE TO EXPLAIN DRAMATIC PROGNOSIS DIFFERENCES BETWEEN EARLY AND ADVANCED‐STAGE IN ENKTL PATIENTS	5
Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR)	5
Molecular diagnostics and reporting in lymphoid malignancies: Current status and beyond	5
New drugs and pharmacological interactions in real life	5
SAKK 38/19: ASSESSING A CTDNA AND PET‐ORIENTED THERAPY IN PATIENTS WITH DLBCL. A MULTICENTER, OPEN‐LABEL, PHASE II TRIAL	5

Role of autologous stem cell transplantation or salvage chemotherapy in relapsed/refractory classical Hodgkin lymphoma patients after immune checkpoint inhibitors	5
Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4‐positive peripheral T‐cell lymphoma and relapsed or refractory cutaneous T‐cell lymphoma: A post‐marketing s	5
Primary testicular lymphoma demonstrates overexpression of the Wilms tumor 1 gene and different mRNA and miRNA expression profiles compared to nodal diffuse large B‐cell lymphoma	5
Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions	5
A single‐center experience of low‐dose radiotherapy for primary extranodal marginal zone lymphoma of bronchus‐associated lymphoid tissue (BALT)	5
Personalized monitoring of circulating tumor DNA by a specific signature of trackable mutations after chimeric antigen receptor t‐cell therapy in non‐Hodgkin B cell lymphoma	5
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment for chronic lymphocytic leukemia/ small lymphocytic leukemia: a single‐arm study	5
Issue Information	5
Patient‐ versus clinician‐reported symptoms in the POLARIX study	5
Proteomic profiling differentiates classic Hodgkin lymphoma with and without skeletal involvement at the time of diagnosis	5
ONKOFRAIL: PERSONALIZATION OF A PHYSICAL EXERCISE PROGRAM IN OLDER PATIENTS WITH LYMPHOMA	5
TET2 regulates extranodal NK/T cell lymphoma progression through regulation of DNA methylation	5
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective	5
Activation of the Novel Tumor Suppressor SAMHD1 Inhibits Cell Growth and Induces Interferon‐beta (IFN‐β) Gene Expression in Classical Hodgkin Lymphoma (cHL)	5
NX‐0255 AND NX‐1607, SMALL MOLECULE INHIBITORS OF CBL‐B, ARE EFFICACIOUS IN COMBINATION WITH ADOPTIVE CELL THERAPY OR RITUXIMAB IN PRECLINICAL MOUSE MODELS OF LYMPHOMA	5
INCREASED SOLUBLE SERUM CD163 (SCD163) LEVELS PREDICT A SHORT DISEASE FREE SURVIVAL IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)	5
ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY	5
Issue Information	5
A five‐gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia	5
CHARACTERIZATION OF CANCER ASSOCIATED FIBROBLASTS IN CLASSICAL HODGKIN LYMPHOMA	5
Proteomic profiling identifies apoptotic deregulation predictive of histological transformation in follicular lymphoma	5
Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials	5
Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial	5
Safety of acalabrutinib treatment in very old (≥80 y) and/or frail patients with chronic lymphocytic leukemia ‐ interim safety analysis of the ongoing phase II CLL‐Frail trial	4
Next Generation Sequencing in routine diagnostics of mature non‐Hodgkin’s lymphomas. A single‐center real‐life data study	4
AN OPEN‐LABEL TRIAL OF ORAL CA‐4948 AN IRAK4 INHIBITOR COMBINED WITH IBRUTINIB IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES	4
The Immunobiology of histologic transformation in follicular lymphoma: a multi‐omic case‐control study	4
Treatment‐related toxicity disparities in adult Hispanic acute lymphoblastic leukemia patients receiving pegaspargase‐based regimens: A multicenter electronic health research network study	4
ANALYSIS TREATMENT OUTCOME OF 46 REFRACTORY/RELAPSED PEDIATRIC MATURE B CELL LYMPHOMA PATIENTS‐MULTI‐CENTER EXPERIENCE FROM CHINA	4
NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY	4
Robust Bruton’s tyrosine kinase (BTK) degradation with NX‐5948, an oral BTK degrader, in a first‐in‐human phase 1a trial in relapsed/refractory B cell malignancies	4
Novel agents in relapsed/refractory diffuse large B‐cell lymphoma	4
PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5	4
Liposomal‐encapsulated doxorubicin supercharge‐containing front‐line treatment improves response rates in primary mediastinal large B‐cell lymphoma and mediastinal gray zone lymphoma	4
THE RNA M6A READER YTHDF2 REGULATES ACER2‐CERAMIDE METABOLIC AXIS TO PROMOTE TUMORIGENESIS OF DIFFUSE LARGE B‐CELL LYMPHOMA	4
Brentuximab vedotin (BV) + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): incidence and management of peripheral neuropathy (PN) in a multi‐institution cohort	4
Brentuximab Vedotin‐Nivolumab alone and then with Rituximab‐Cyclophosphamide‐Doxorubicin‐Prednisone as Frontline Therapy of Primary Mediastinal Large B‐cell Lymphoma	4
Secondary cancer is the leading cause of death 15 years or more after diagnosis of early‐stage Hodgkin lymphoma	4
REAL‐WORLD TREATMENT PATTERNS, DISCONTINUATION AND CLINICAL OUTCOMES IN PATIENTS WITH B‐CELL LYMPHOPROLIFERATIVE DISEASES TREATED WITH BTK INHIBITORS IN CHINA	4
Brentuxinmab vedotin, alone or combine with bendamustine in the treatment of natural killer T cell lymphoma	4
CAR‐T CELLS RADICALLY MODIFY THE MANAGEMENT OF RELAPSED/REFRACTORY PRIMARY CEREBRAL LYMPHOMAS. REAL LIFE RESULTS OF THE FRENCH LOC NETWORK	4
Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysis	4
Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphoma	4
A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non‐Hodgkin lymphoma	4
CRISPR/CAS9 SCREENING REVEALS SOS1 PARTICIPATE IN ASPARAGINASE RESISTANCE IN NK/T CELL LYMPHOMA	4
[¹⁸F]‐FDG PET radiomic model as prognostic biomarker in diffuse large B‐cell lymphoma	4
Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL)	4
PERVASIVE HYPERMUTATION OF SUPER‐ENHANCER REGIONS DYSREGULATES ONCOGENE EXPRESSION IN DIFFUSE LARGE B‐CELL LYMPHOMA	4
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study	4
Long‐term outcomes with mogamulizumab alone or in combination with other therapies for the treatment of cutaneous t‐cell lymphoma	4
CLINICAL FEATURES AND PROGNOSIS OF PATIENTS COEXISTING WITH FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B‐CELL LYMPHOMA: A RETROSPECTIVE OBSERVATIONAL STUDY	4
A sub‐population of cells expressing MYC and BCL2 without BCL6 refines the definition of double expressor lymphoma (DEL)	4
Deciphering the role of macrophages and T cells in primary central nervous system lymphoma: tumour aggressiveness and response to immunotherapies	4
New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model	4
Differences in baseline PET/CT lymphoma distribution patterns between DLBCL‐NOS and high‐risk DLBCL patients	4
Long‐term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients	4
SPATIALLY‐RESOLVED TRANSCRIPTOMICS DEFINE CLINICALLY RELEVANT SUBSETS OF MACROPHAGES IN DIFFUSE LARGE B‐CELL LYMPHOMA	4
NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826	4
Safety and efficacy of brentuximab vedotin in Chinese adults with CD30+ peripheral T‐cell lymphoma: an interim analysis from a prospective, observational, real‐world study	4
Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study	4
EFFICACY OF FRONT‐LINE IMMUNOCHEMOTHERAPY FOR TRANSPLANT‐INELIGIBLE MANTLE CELL LYMPHOMA: A NETWORK META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	4
Molecular remission is an independent predictor of progression‐free survival in patients with Waldenström macroglobulinemia treated with chemo‐immunotherapy: Results from the FIL_BIOWM study	4
A PHASE 2 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE (LONCA) VERSUS (VS) IDELALISIB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) – LOTIS‐6	4
PILOT PHASE II STUDY OF SELINEXOR IN COMBINATION WITH IFOSFAMIDE, ETOPOSIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMAS (R/R PTCLS)	4
Reappraisal of the role of radiation therapy in lymphoma treatment	4
MIPI53. A NEW PROGNOSTIC INDEX FOR MANTLE CELL LYMPHOMA	4
THE TUMOR MICROENVIRONMENT OF HODGKIN LYMPHOMA AT SINGLE CELL RESOLUTION	4
Analyses of a patient with 3 sequential Post Transplant Lymphoprolierative Disease (PTLD) biopsies reveal persistence of Histone 1 gene mutation, suspected to mediate PTLD	4
Diagnosis of chronic B‐cell lymphoproliferative disease in peripheral blood = how machine learning may help to the interpretation of flow cytometry data	3
Pre‐treatment health‐related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA‐BERIT) experienc	3
Outcomes of hematopoietic cell transplantation for transformed follicular lymphoma	3
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY	3
Langerhans cell histiocytosis: Version 2021	3
Malnutrition diagnosed by GLIM criteria better predicts long‐term outcomes for patients with non‐Hodgkin's lymphoma: A prospective multicenter cohort study	3
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia	3
How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia	3
EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS	3
	3
GENETIC SUBTYPE GUIDED RITUXIMAB‐BASED IMMUNOCHEMOTHERAPY IMPROVES OUTCOME IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: FIRST REPORT OF A RANDOMIZED PHASE 2 STUDY	3
A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents	3
A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B‐cell malignancies: waveLINE‐006	3
Are we reaching the maximum cure rate for Hodgkin lymphoma?	3
CD38 expression is an important prognostic marker in diffuse large B‐cell lymphoma	3
PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	3
Correction to Staging FDG‐avidity in extranodal marginal zone lymphoma (EMZL) by disease location	3
Circ_0009910 shuttled by exosomes regulates proliferation, cell cycle and apoptosis of acute myeloid leukemia cells by regulating miR‐5195‐3p/GRB10 axis	3
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study	3
ROLE OF MAINTENANCE RITUXIMAB AFTER FIRST‐LINE BENDAMUSTINE + RITUXIMAB OR R‐CHOP IN PATIENTS WITH MANTLE CELL LYMPHOMA FROM A LARGE US REAL‐WORLD COHORT	3
Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials	3
Early Detection and Central Nervous System Prophylaxis in Patients With High‐Risk Features of Primary Lymphoma of the Female Genital Tract: The Key to Improved Prognosis	3
What's new in peripheral T‐cell lymphomas	3
PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N‐AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMA	3
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia	3
Successful early treatment combining remdesivir with high‐titer convalescent plasma among COVID‐19‐infected hematological patients	3
Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head‐to‐Head Trial of Acalabrutinib Versus Ibrutinib	3